| (Values in U.S. Thousands) | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sep, 2023 |
| Sales | 2,610 | 2,130 | 2,360 | 990 | 830 |
| Sales Growth | +22.54% | -9.75% | +138.38% | +19.28% | +9.21% |
| Net Income | -16,440 | -16,310 | -20,130 | -20,210 | -22,250 |
| Net Income Growth | -0.80% | +18.98% | +0.40% | +9.17% | +25.06% |
Omega Therapeutics Inc (OMGA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Omega Therapeutics Inc. is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc. is based in CAMBRIDGE, Mass.